Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia

N/ACompletedNCT04542044

University Hospital, Geneva40 enrolled

Overview

The purpose of this study is to evaluate the strategy of investigators for outpatients SARS-CoV-2 moderate pneumonia management in terms of efficacy and patient safety. The investigators ultimate goal is to validate first wave management strategy in order to support the investigators future approach in the event of a second wave, and spare the hospital resources by safely keeping at home as many patients as possible.

The investigators focused on participants consulting in the emergency department at the HUG who remained in an outpatient setting, with pneumonia and moderate illness, defined by individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SaO2) \>93% on room air and no other hospitalization criteria (CURB 65 score below 2points). For patients' follow-up, the investigators have created an aftercare ambulatory unit, open 5/7 days. The investigators were able to conduct 64 consultations between April 2 and May 5, 2020. Every participant had suspected or confirmed SARS-CoV-2 pulmonary tract infection. The follow-up data was entered into DPI (patient's medical record at HUG) on a specific consultation form. Patients followed in the investigators consultation were contacted between 30 and 60 days after diagnosis by the Covicare team. The Covicare team is call-center composed of medical students and primary care physicians who remotely followed patients with COVID-19 by calling them by phone or telemedicine every day or every other day depending on patients' needs and health status. The investigators will export data from RedCap concerning post-hospitalization, satisfaction survey on our care and oral consent for use of data (ARGOS study CCER number 2020-01273).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Covid19 Pneumonia

Interventions

management strategy of outpatient with mild to moderate SARS-CoV-2 pneumoniaOTHER

Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * All persons with suspected or confirmed SARS-CoV-2 pneumonia who consulted in the emergency department of the HUG without criteria for hospitalization4 (Pneumonia with CURB-65 \>= 2 or new O2 dependency or increased O2 requirements or sustained respiratory rate≥20 min or decompensated comorbidity or major alteration of the general state) and who have been scheduled for outpatient follow-up in HUG. Exclusion Criteria: * Patients with hospitalization criteria * Refusal to consent documentation found in the computerized patient record or oral refusal consent during follow up call.

Locations (1)

Geneva University Hospital

Geneva, Switzerland

Outcomes

Primary Outcomes

Secondary hospitalization(s) or death COVID-19 related

Time frame: 30 to 60 days from diagnosis

Secondary Outcomes

severity of COVID-19 disease

severity of COVID-19 disease on a 7-points ordinal scale (1: not hospitalized, no limitation of activities; 2: not hospitalized, limitation of activities; 3: hospitalized, not requiring supplementary oxygen; 4: hospitalized, requiring supplementary oxygen; 5: hospitalized, on non-invasive mechanical ventilation; 6: hospitalized, on invasive mechanical ventilation or ECMO; 7: death),

Time frame: 30 to 60 days from diagnosis

patient satisfaction with management strategies

Satisfaction Survey of outpatient management

Time frame: 30 to 60 days from diagnosis

Saved costs

estimation of saved costs compared with a strategy of hospitalization of all COVID-19 related pneumonia cases.

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.